| | | |   | | | | By Lev Facher Kristen Norman for STAT A devastating diagnosis. A fight against time. And an 'epic' journey that galvanized a new movement for ALS patients. Read More | | By Ed Silverman Adobe A new study finds a so-called "skinny label" for a generic version of a pricey cancer drug cut costs for patients on the medicine. Read More | | By Rachel Cohrs Steven Senn/AP Medicare took a highly unusual step to restrict access to the controversial, pricey Alzheimer's drug Aduhelm. Read More | | Sponsor content by Amgen How does a molecule go from discovery to development? Getting a medicine from the lab into the hands of patients doesn't come easily, as David Reese, Executive Vice President, Research and Development at Amgen, will tell you. "It takes more than a village — it takes an army that has worked for many years. That's why we're here, it's why I come to work every day." Hear from David, scientists, and researchers about what it takes to bring a molecule from discovery to development. | | By Adam Feuerstein Adobe Called “targeted RNA degraders,” this emerging technology will go after targets that traditional drug-development methods can’t reach. Read More | |
No comments